The Novo Nordisk name change is real, but it is a corporate rebrand, not a medication change. The company will call itself “Novo” in everyday communications. Novo Nordisk A/S remains its legal name, and the announcement did not rename Wegovy or Ozempic, alter their ingredients, or change a prescription already written.
That is the plain answer. The new identity says something about how the company wants to compete. It does not, by itself, say anything new about how semaglutide works or whether it is right for one person.
Novo Nordisk name change: what happened
On September 14, 2026, the company announced the Novo rebrand. The public-facing name is now “Novo,” while the legal global company name stays Novo Nordisk A/S. The familiar Apis bull remains in an updated logo, and the new slogan is “Lasting Health Starts Now.”
The announcement also introduced “The Novo Way,” four working principles called Customer Obsession, Competitiveness, Clarity, and Care & Integrity. In the company’s own words, the brand and culture are meant to bring more “focus, speed and impact.” That is a description of how Novo wants to operate, not a new medical claim.
As of September 18, 2026, the day this article was written, this September 14 release is the primary document behind the news. It says the day-to-day name and visual identity are changing. It does not announce a drug recall, a formula change, a new dose, or a new prescribing rule.
What changes for Wegovy, Ozempic, or the Wegovy pill?
For a person with a current prescription, nothing in this announcement changes the medicine. Wegovy, Ozempic, and the Wegovy pill keep their product names. Their prescribing information still governs what each product contains, what it is used for, and its warnings.
The current Wegovy prescribing information is revised June 2026, while the current Ozempic prescribing information is revised May 2026. They still list the familiar product names, packager details, and NDCs, or National Drug Codes—the identifiers attached to marketed drug packages. The September rebrand release gives no timetable for changing any carton or package display.
The evidence behind semaglutide does not move with a logo, either. In STEP 1, a 2021 trial of 1,961 adults without diabetes, average weight change after 68 weeks was 14.9% lower with semaglutide and 2.4% lower with placebo (Wilding et al., New England Journal of Medicine). In SELECT, a 2023 trial of 17,604 adults with existing heart disease and overweight or obesity but no diabetes, the main cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group (Lincoff et al., New England Journal of Medicine). Those are trial averages, not a forecast for an individual.
What the Novo rebrand signals—and what it does not
Novo says the shorter identity is meant to be more memorable and to sharpen its competitive edge in a faster, more consumer-focused market. “Competitiveness” is now one of the four principles in The Novo Way. The company also says its purpose has not changed.
The competitive context is hard to miss, but the release does not name Eli Lilly. Novo and Lilly compete in obesity medicine, and their recent dispute concerns how Zepbound and Wegovy trial results are presented in advertising. Our explainer on the Novo Nordisk–Lilly lawsuit keeps that case separate from clinical evidence. The Zepbound versus Wegovy comparison explains the patient-facing differences between tirzepatide and semaglutide.
A new corporate identity does not settle that contest. It does not make one drug better for everyone, erase differences between the two molecules, or replace a provider’s review with a brand preference.
What the name change does not mean
It is not a safety alert. It is not a change to how a current prescription is filled. It is not an instruction to switch products, and it does not turn “Novo” into the name of a new drug.
It also does not make every use of the word semaglutide a Novo product. Semaglutide is the name of the molecule. Wegovy and Ozempic are specific branded products, while a compounded preparation is made for an individual prescription under a different framework. A company rebrand does not collapse those categories.
What to watch next
The practical thing to watch is official product information. If a package design, packager name, or NDC changes later, the updated label and pharmacy record will show it. The September 14 announcement does not provide a packaging schedule, so a new corporate logo should not be treated as evidence that the medication inside has changed.
There is also a separate pipeline milestone ahead. In its August 4, 2026 second-quarter investor presentation, Novo said it expected a U.S. decision on CagriSema in the fourth quarter of 2026. CagriSema is an investigational combination of cagrilintide and semaglutide. That decision would be a regulatory event; the rebrand is not. What CagriSema is belongs in its own clinical explanation.
Where compounded semaglutide fits
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The Novo name change does not turn that compounded preparation into Wegovy or Ozempic, and the branded trials above did not test Promise’s compounded formulation.
A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. At Promise, a licensed provider reviews every request and not everyone qualifies.
The useful distinction is still the same after the rebrand: a corporate name tells you who stands behind a brand, while a prescription and pharmacy label tell you exactly what product was selected for you.
